Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis

World Psychiatry

Volumn 16, Issue 1, 2017, Pages 77-89

  Galling, Britta ^a,b,c   Roldán, Alexandra ^d   Hagi, Katsuhiko ^b,e   Rietschel, Liz ^f   Walyzada, Frozan ^b   Zheng, Wei ^g   Cao, Xiao Lan ^h   Xiang, Yu Tao ⁱ   Zink, Mathias ^j   Kane, John M ^b,c,k,l   Nielsen, Jimmi ^m,n   Leucht, Stefan ^o   Correll, Christoph U ^b,c,k,l  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e Tamura Pharmaceutical Co Ltd   (Japan)

^f UNIVERSITY OF BERN   (Switzerland)

^g GUANGZHOU MEDICAL UNIVERSITY   (China)

^h CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

ⁱ UNIVERSITY OF MACAU   (Macao)

^j UNIVERSITY OF HEIDELBERG   (Germany)

^k FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^l ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^m AALBORG UNIVERSITY HOSPITAL   (Denmark)

ⁿ AALBORG UNIVERSITY   (Denmark)

^o TECHNICAL UNIVERSITY OF MUNICH   (Germany)

more..

Author keywords

Antipsychotics; aripiprazole; augmentation; clozapine; monotherapy; polypharmacy; schizophrenia

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; OLANZAPINE; PALIPERIDONE; PIMOZIDE; PROLACTIN; QUETIAPINE; RISPERIDONE; SERTINDOLE; SULPIRIDE; ZIPRASIDONE;

ARTICLE; BODY WEIGHT; COMBINATION DRUG THERAPY; COMPARATIVE EFFECTIVENESS; DEPRESSION; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MONOTHERAPY; NEGATIVE SYNDROME; POLYPHARMACY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS; SCHIZOPHRENIA; SYSTEMATIC REVIEW;

EID: 85010634288     PISSN: 17238617     EISSN: 20515545     Source Type: Journal    
DOI: 10.1002/wps.20387     Document Type: Article

References (85)

1. Hegarty JD, Baldessarini RJ, Tohen M et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994;151:1409-16.
2. Jones PB, Barnes TRE, Davies L et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-87.
3. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.
4. Robinson DG, Woerner MG, McMeniman M et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 2004;161:473-9.
5. Jääskeläinen E, Juola P, Hirvonen N et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull 2013;39:1296-306.
6. Falkai P, Wobrock T, Lieberman J et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: Acute treatment of schizophrenia. World J Biol Psychiatry 2005;6:132-91.
7. Moore TA, Buchanan RW, Buckley PF et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007;68:1751-62.
8. Buchanan RW, Kreyenbuhl J, Kelly DL et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36:71-93.
9. Lehman AF, Lieberman JA, Dixon LB et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161(Suppl. 2):1-56.
10. Goodwin G, Fleischhacker W, Arango C et al. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol 2009;19:520-32.
11. Chinese Medical Association. Guideline for the prevention and treatment of psychiatric disorders in China. Beijing: Chinese Medical Association, 2003.
12. Gallego JA, Bonetti J, Zhang J et al. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 2012;138:18-28.
13. Correll CU, Shaikh L, Gallego JA et al. Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior. Schizophr Res 2011;131:58-62.
14. Ganguly R, Kotzan JA, Miller LS et al. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 2004;65:1377-88.
15. Clark RE, Bartels SJ, Mellman T et al. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 2002;28:75-84.
16. Nielsen J, Dahm M, Lublin H et al. Psychiatrists’ attitude towards and knowledge of clozapine treatment. J Psychopharmacol 2010;24:965-71.
17. Correll CU, Gallego JA. Antipsychotic polypharmacy. Psychiatr Clin North Am 2012;35:661-81.
18. Faries D, Ascher-Svanum H, Zhu B et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 2005;5:26.
19. Tapp A, Wood AE, Secrest L et al. Combination antipsychotic therapy in clinical practice. Psychiatr Serv 2003;54:55-9.
20. Correll CU, Rummel-Kluge C, Corves C et al. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009;35:443-57.
21. Barbui C, Signoretti A, Mulè S et al. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull 2009;35:458-68.
22. Gallego JA, Nielsen J, De Hert M et al. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf 2012;11:527-42.
23. Rupnow MFT, Greenspan A, Gharabawi GM et al. Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. Curr Med Res Opin 2007;23:2815-22.
24. Zhu B, Ascher-Svanum H, Faries DE et al. Cost of antipsychotic polypharmacy in the treatment of schizophrenia. BMC Psychiatry 2008;8:19.
25. Baandrup L, Sørensen J, Lublin H et al. Association of antipsychotic polypharmacy with health service cost: a register-based cost analysis. Eur J Health Econ 2012;13:355-63.
26. De Hert M, Detraux J, van Winkel R et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2012;8:114-26.
27. De Hert M, Dobbelaere M, Sheridan EM et al. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 2011;26:144-58.
28. Correll CU. Balancing efficacy and safety in treatment with antipsychotics. CNS Spectr 2007;12(Suppl. 17):12-20.
29. Misawa F, Shimizu K, Fujii Y et al. Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects? A cross-sectional study. BMC Psychiatry 2011;11:118.
30. Trikalinos TA, Churchill R, Ferri M et al. Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. J Clin Epidemiol 2004;57:1124-30.
31. Taylor DM, Smith L, Gee SH et al. Augmentation of clozapine with a second antipsychotic – a meta-analysis. Acta Psychiatr Scand 2012;125:15-24.
32. Sommer IE, Begemann MJH, Temmerman A et al. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull 2012;38:1003-11.
33. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002;106:323-30.
34. Stahl SM. Antipsychotic polypharmacy: evidence based or eminence based? Acta Psychiatr Scand 2002;106:321-2.
35. Stroup DF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-12.
36. Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
37. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
38. Ventura J, Lukoff KH, Nuechterlein KH et al. Manual for the Expanded Brief Psychiatric Rating Scale. Int J Methods Psychiatr Res 1993;3:227-44.
39. Andreasen NC. The Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa, 1984.
40. Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa, 1984.
41. Guy W. ECDEU assessment manual for psychopharmacology, revised. Rockville: US Department of Health, Education, and Welfare, 1976.
42. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
43. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res 1990;3:247-51.
44. Hall RCW. Global Assessment of Functioning: a modified scale. Psychosomatics 1995;36:267-75.
45. Higgins JPT, Altman DG, Gøtzsche PC et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
46. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
47. Chen J-X, Su Y-A, Bian Q-T et al. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: a randomized, double-blind, placebo-controlled, dose-response study. Psychoneuroendocrinology 2015;58:130-40.
48. Liu L, Qi SG, Dong XH et al. A placebo-controlled trail of adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia. Chin J Health Psychol 2011;19:1288-90.
49. Leucht S, Rothe P, Davis JM et al. Equipercentile linking of the BPRS and the PANSS. Eur Neuropsychopharmacol 2013;23:956-9.
50. Egger M, Davey Smith G, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
51. Duval S, Tweedie R. A nonparametric “trim and fill” method of accounting for publication bias in meta-analysis. J Am Stat Assoc 2000;95:89-98.
52. Liu YD, Huang WF, Huang SJ. A control study of clozapine combined with fluphenazine in refractory schizophrenia. Med J Chin People's Health 2008;20:1274.
53. Friedman JI, Lindenmayer J-P, Alcantara F et al. Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy. Neuropsychopharmacology 2011;36:1289-95.
54. Gunduz-Bruce H, Oliver S, Gueorguieva R et al. Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia. Schizophr Res 2013;143:344-7.
55. Chang JS, Ahn YM, Park HJ et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008;69:720-31.
56. Fan X, Borba CPC, Copeland P et al. Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatr Scand 2013;127:217-26.
57. Fleischhacker WW, Heikkinen ME, Olié J-P et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2010;13:1115-25.
58. Guan Y. The efficacy and safety of aripiprazole combined with clozapine in the treatment of refractory schizophrenia. J Bengbu Med Coll 2014;39:1084-6.
59. Muscatello MRA, Bruno A, Pandolfo G et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophr Res 2011;127:93-9.
60. Sun WH, Chen Y, Wang KY. The study of combining clozapine and aripiprazole for the treatment of negative symptoms of schizophrenia. Med J Chin People's Health 2012;24:2592-4.
61. Lin P, Cheng J, Mao G. Paliperidone ER combined with clozapine in the treatment of patients with refractory schizophrenia. Hebei Med 2014;20:1668-71.
62. Freudenreich O, Henderson DC, Walsh JP et al. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res 2007;92:90-4.
63. Anil Yağcioğlu AE, Kivircik Akdede BB, Turgut TI et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 2005;66:63-72.
64. Honer WG, Thornton AE, Chen EYH et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006;354:472-82.
65. Josiassen RC, Joseph A, Kohegyi E et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2005;162:130-6.
66. Hu X. Clozapine combined with risperidone in replacement of single clozapine in schizophrenia treatment. Med J Chin People's Health 2014;26:21-2.
67. Weiner E, Conley RR, Ball MP et al. Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology 2010;35:2274-83.
68. Nielsen J, Emborg C, Gydesen S et al. Augmenting clozapine with sertindole: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol 2012;32:173-8.
69. Shiloh R, Zemishlany Z, Aizenberg D et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 1997;171:569-73.
70. Jiang T, Zhang YF, Chi Y et al. The treatment efficacy of clozapine combined with ziprasidone in refractory schizophrenia. Clin J Postgrad Med 2011;34:62-4.
71. Muscatello MRA, Pandolfo G, Micò U et al. Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study. J Clin Psychopharmacol 2014;34:129-33.
72. Shim JC, Shin JG, Kelly DL et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 2007;164:1404-10.
73. Kane JM, Correll CU, Goff DC et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry 2009;70:1348-57.
74. Lee BJ, Lee SJ, Kim MK et al. Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidone. Clin Psychopharmacol Neurosci 2013;11:60-6.
75. Ou Y, Shi J, Chen F. The effect of aripiprazole on serum levels of Insulin-like Growth factor-1 in schizophrenia treatment with olanzapine. Chin J Health Psychol 2014;22:161-3.
76. Yasui-Furukori N, Kaneda A, Sugawara N et al. Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients. J Psychopharmacol 2012;26:806-12.
77. Zhao YQ. A control study on aripiprazole reduces risperidone-induced weight gain and increase of prolactin in patients with schizophrenia. Sichuan Ment Health 2013;26:122-3.
78. Zhou P, Liu LQ, Hao JF et al. The study of aripiprazole on preventing the hyperprolactinemia induced by antipsychotics on female. J Int Psychiatry 2014;41:69-72.
79. Liang Y, Liu MD. A control study of aripiprazole combined with low-dose clozapine in female schizophrenia. J Clin Psychosom Dis 2013;10:3.
80. Kotler M, Strous RD, Reznik I et al. Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology. Int Clin Psychopharmacol 2004;19:23-6.
81. Millan MJ, Fone K, Steckler T et al. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol 2014;24:645-92.
82. Rabinowitz J, Berardo CG, Bugarski-Kirola D et al. Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis. Schizophr Res 2013;150:339-42.
83. Correll CU, Skuban A, Ouyang J et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2015;172:870-80.
84. Kane JM, Zukin S, Wang Y et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol 2015;35:367-73.
85. Furukawa TA, Levine SZ, Tanaka S et al. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. JAMA Psychiatry 2015;72:14-21.